Moss Report on Kidney Cancer
Alternative & Conventional Kidney Cancer Treatments (2019 Update)
What’s New In Kidney Cancer Treatment
A discussion of clinical trials evaluation of initial treatment with a combination of the checkpoint inhibitorsnivolumab (Opdivo®) + ipilimumab (Yervoy®) vs. the antiangiogenic agent sunitinib (Sutent®). James Allison, PhD, is the head of immunology at the University of Texas M.D. Anderson Cancer Center, Houston. While at the University of California, Berkeley, he invented an important new class of medications called “immune checkpoint inhibitors.” Allison is currently working on combining these medications with cancer-killing viruses, such as Newcastle Disease Virus (NDV) vaccines. These are already available at several foreign clinics. One of the most significant advances of recent years has been the development and FDA approval of an anti-cancer virus vaccine, Reolysin® (pelareorep). The 2019 Moss Report discusses this new medicine and its associated clinical trials.
Kidney Cancer Treatment
The Moss Report on kidney cancer contains comprehensive, up-to-date information on conventional, integrative, experimental, complementary, CAM, dietary, and alternative kidney cancer treatments and other matters of urgent concern to cancer patients. We also discuss useful methods for determining whether or not a patient will benefit appreciably from various treatments.
Moss Report on kidney cancer also includes description and addresses of innovative and alternative cancer treatment centers, in the US and abroad.
This 500-page report features a comprehensive discussion of the treatment and prevention of cancer of the kidney – also known as renal cell carcinoma – from the best techniques of surgery, radiation and chemotherapy to the latest complementary and alternative (CAM) approaches. New this year is a discussion of improvements in how science is harnessing the immune system to fight these cancers. This includes very encouraging results with immune checkpoint inhibitors such as nivolumab (Opdivo®), along with an explanation of which kidney cancer patients are likely to respond to this important new kind of treatment.
There is also an up-to-the-minute discussion of the combination of stereotactic radiation and immune therapy, in which the radiation actually creates a kind of vaccine in the subject. No patient with kidney cancer (RCC) or their loved ones should be without this outstanding Moss Report.
Discounts and Savings Available
Purchase both the E-Book and
Printed Moss Report and save $100.*
Purchase a Moss Report and
Schedule a Consultation and save $100.*
If you are a Medical Professional and refer patients to Moss Reports, click here find out more about our advocate program.
*Discounts applied when purchased together at check-out.
“I can’t tell you what a wealth of information we found and how helpful and informative the Report was. Thank you. My eyes were truly opened.” — L. C.
“Thank you very much. Your report is very helpful and comprehensive.” —B. S.
“We have received your report.. and sincerely appreciate your thoroughness and writing style.” —R. D.
“I have really been disappointed with radiation and chemotherapy and have been so glad that you steered me to more viable alternatives.” —W. V.
“Thanks for your help. Your service is a marvelous resource, tremendously helpful for those of us sifting through the masses of information that we have to go through in these really stressful situations.” — S. A.
Table of Contents
- A QUICK GUIDE TO CAM CANCER TREATMENTS
- GREEN LIGHT TREATMENTS: WELL RESEARCHED APPROACHES
- AMBER LIGHT TREATMENTS FOR CANCER: EFFICACY AND SAFETY STILL UNCLEAR
- RED LIGHT TREATMENTS: POORLY RESEARCHED (OR DOWNRIGHT DANGEROUS)
- CONVENTIONAL TREATMENT SECTION
- TYPES OF RENAL CELL CARCINOMA
- CAUSES OF KIDNEY CANCER
- RED MEAT AND KIDNEY CANCER
- PARANEOPLASTIC SYNDROMES
- STAGING AND TREATMENT
- LAPAROSCOPIC SURGERY
- TREATMENT BY STAGES
- RADIATION THERAPY
- NCCN RECOMMENDATIONS
- DRUGS APPROVED FOR KIDNEY (RENAL CELL) CANCER
- ANTI-ANGIOGENIC AGENTS FOR KIDNEY CANCER (RCC)
- CLINICAL TRIALS
- CHECKPOINT INHIBITORS
- SPONTANEOUS REGRESSIONS
- IMMUNE THERAPY + STEREOTACTIC RADIATION (ISABR)
- CAM AND KIDNEY CANCER
- CIMETIDINE AND KIDNEY CANCER (RCC)
- TOP SUPPLEMENTS (THE SHORT LIST)
- ANTI-CANCER PLAN ON A TIGHT BUDGET
- ANTI-CANCER RECIPES
- THE HALLMARKS OF CANCER
- A NEW MODEL FOR CANCER TREATMENT
- INNOVATIVE SURGERY
- INNOVATIVE RADIATION THERAPY
- INNOVATIVE CHEMOTHERAPY
- NAUSEA AND VOMITING
- MOUTH SORES (STOMATITIS)
- ZINC SULFATE
- NERVE PAIN
- HAIR LOSS
- PICKLE JUICE REMEDY
- CHEMOSENSITIVITY TESTING
- TARGETED THERAPIES
- PRECISION MEDICINE INITIATIVE
- ANTI-ANGIOGENESIS DRUGS
- MOLECULAR AND GENOMIC TESTING
- CIRCULATING TUMOR CELLS (CELLSEARCH)
- MONOCLONAL ANTIBODIES
- IMMUNE CHECKPOINT BLOCKADE (ICB)
- CANCER STEM CELLS (CSCS)
- DIETARY COMPOUNDS THAT KILL CANCER STEM CELLS (CSCS)
- PHYSICAL ACTIVITY AND EXERCISE
- FASTING AND THE KETOGENIC DIET
- A COST-FREE WAY TO PREVENT CANCER RECURRENCES
- CALORIC RESTRICTION
- PRACTICAL NOTES ON FASTING
- TOP TEN SUPPLEMENTS (THE EXPOSITION)
- FOOD AND CANCER PREVENTION
- VITAMINS, MINERALS & ANTIOXIDANTS
- THE CONCURRENT USE DEBATE
- CONCURRENT USE OF ANTIOXIDANTS AND RADIATION
- HERBS, SPICES AND BOTANICALS
- SOUND, LIGHT AND ELECTRICITY
- CANCER IMMUNOTHERAPY
- VIRAL THERAPY (ONCOLYTIC VIRUSES)
- DRUGS NEW AND OLD
- INNOVATIVE CANCER CLINICS
- FINDING AN INTEGRATIVE PHYSICIAN
- INTEGRATIVE ONCOLOGY DEPARTMENTS
- AMERICAN CLINICS
- INTERNATIONAL CLINICSSUPPLEMENTS AND SURGERY
- CAM AND FATIGUE
- POPULAR BUT UNLIKELY TREATMENTS